Volume 1.03 | Jan 29

Prostate Cell News 1.03, January 29, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Basal Epithelial Stem Cells are Efficient Targets for Prostate Cancer Initiation
Findings provide evidence in support of basal epithelial stem cells as one target cell for prostate cancer initiation and demonstrates the propensity of primitive cells for tumorigenesis. [Proc Nat Acad Sci]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies


Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients
Patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine. [Press release from Dana-Farber Cancer Institute discussing the online prepublication in the Journal of Clinical Oncology]

Biochemical Profile May Help Diagnose and Determine Aggressiveness of Prostate Cancer
Researchers report how spectroscopic analysis of the biochemical makeup of prostate glands accurately identified the location of tissue confirmed to be malignant by conventional pathology. [Press release from Massachusetts General Hospital discussing the online prepublication in Science Translational Medicine]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies



Inherited Genetic Variant Predisposes to Aggressive but Not Indolent Prostate Cancer
This study demonstrates that inherited variants predisposing to aggressive but not indolent prostate cancer exist in the genome, and suggests that the clinical potential of such variants as potential early markers for risk of aggressive prostate cancer should be evaluated. [Proc Nat Acad Sci]

Role of Cationic Channel TRPV2 in Promoting Prostate Cancer Migration and Progression to Androgen Resistance
Findings establish a role for transient receptor potential vanilloid 2 (TRPV2) in prostate cancer progression to the aggressive castration-resistant stage, prompting evaluation of TRPV2 as a potential prognostic marker and therapeutic target in the setting of advanced prostate cancer. [Cancer Res]

Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems
Researchers constructed and analyzed a mathematical model of the integration between hormone growth factor signaling, androgen receptor activation, and the expression of cyclin D and prostate-specific antigen in human LNCaP prostate adenocarcinoma cells. [PLoS ONE]

Molecular Characterisation of ERG, ETV1 and PTEN Gene Loci Identifies Patients at Low and High Risk of Death from Prostate Cancer
The study objective was to evaluate the potential clinical significance and natural history of different disease categories by combining ERG/ETV1 gene rearrangements and PTEN gene loss status. [Brit J Cancer]

Gonadotropin-Regulated Testicular RNA Helicase (GRTH/DDX25) Gene: Cell-Specific Expression and Transcriptional Regulation by Androgen in Transgenic Mouse Testis
The regulatory region(s) in the gonadotropin-regulated testicular RNA helicase (GRTH ) gene that is/are required for its cell-specific expression in the testis and human chorionic gonadotropin/androgen dependent expression were investigated in transgenic mice carrying sequential deletions of 5′ flanking sequences of the GRTH gene. [J Cell Biochem]

Androgen Receptor Sequence and Variations in Several Common Prostate Cancer Cell Lines
Researchers used direct nucleotide sequencing to genotype the entire exogenous coding region of the androgen receptor in ten commonly used prostate cancer cell lines. [Cancer Biol Ther]

Hedgehog Signaling Regulates Proliferation of Prostate Cancer Cells Via Stathmin1
Hedgehog signaling regulates proliferation of prostate cancer cells by controlling stathmin1 expression. [Clin Exp Med]


Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
PROSTVAC-VF treatment was evaluated for safety and for prolongation of progression-free survival and overall survival in a randomized, controlled, and blinded phase II study. [J Clin Oncol]

Prostate Cancer Treatment for Economically Disadvantaged Men
The authors compared the types of treatments prostate cancer patients received from county hospitals and private providers as part of a statewide public assistance program. [Cancer]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies


Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy as It Continues to Prioritize Its Portfolio Strategy
Spectrum Pharmaceuticals announced that it is discontinuing development of ozarelix in benign prostatic hypertrophy. [Business Wire]

Poniard Shares Dented by Picoplatin Comparison Data
Shares of a cash-strapped Poniard Pharmaceuticals took a pounding as investors reacted to the news that its cancer therapy picoplatin demonstrated a lower overall survival rate for colorectal cancer patients when compared to a standard combination treatment in a mid-stage trial. [Fierce Biotech]


Advisory Committees; Tentative Schedule of Meetings for 2010 [Food and Drug Administration, United States]

Clarification of SF424 (R&R) Application Instructions for Resubmissions of Revision and Renewal Applications (NOT-OD-10-052) [National Institutes of Health, United States]

NINDS Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows in MD-PhD programs (F31) (PAR-10-091) [National Institutes of Health, United States]

Notice of Availability of Administrative Supplements for Activities to Promote Research Collaborations for Projects Currently Funded by the NCI Division of Cancer Biology (NOT-CA-10-015) [National Cancer Institute, United States]

Participation of NCCAM on RFA-OD-10-009, Recovery Act Limited Competition: Methodology Development in Comparative Effectiveness Research (RC4) (NOT-AT-10-001) [National Center for Complementary and Alternative Medicine, United States]


CHI’s Molecular Medicine Tri-Conference 2010
February 3-5, 2010
San Francisco, United States

AACR/JCA Joint Conference: Cancer Genomics, Epigenomics, and the Development of Novel Therapeutics
February 5-9, 2010
Waikoloa, United States

SMi’s Second Annual Stem Cells 2010
February 15-16, 2010
London, United Kingdom

Keystone Symposia: Stem Cell Differentiation and Dedifferentiation (B4)
February 15-20, 2010
Keystone, United States

5th Annual Stem Cell Summit
February 16, 2010
New York, United States

Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer
February 24-27, 2010
Washington, DC, United States

2010 Genitourinary Cancers Symposium: Progress in Multidisciplinary Management
March 5-7, 2010
San Francisco, United States

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States



Business Development Europe – Cell Therapy Products (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit  here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us